Literature DB >> 16557412

[NSAIDs and COX-2-inhibitors: current status].

C Kneitz1, H P Tony, K Krüger.   

Abstract

NSAIDs (non steroidal anti-inflammatory drugs) are a crucial component for the therapy of pain induced by inflammatory and degenerative joint diseases. Nevertheless their known therapeutic efficacy is contrasted by significant side effects. The recently developed selective COX-2-inhibitors appear to have a better gastrointestinal safety profile, especially relevant to patients with an increased risk for gastrointestinal ulcers and bleeding. However, this effect may similarly be reached by the combination of NSAIDs with proton pump inhibitors. Recent data relate to an elevated myocardial infarction rate in patients using COX-2-inhibitors. This risk may also occur in conventional NSAIDs. Therefore an individual risk calculation is necessary before COX-2-inhibitors or NSAIDs are used. Treatment should be performed with the lowest dosage for the shortest time possible. Combination therapy with salicylic acid seems to abolish the protective effect of COX-2-inhibitors in the GI-tract. Definite risk factors for the treatment with NSAIDs and COX-2-inhibitors have to be defined in further studies providing the best treatment schedule for an individual patient.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16557412     DOI: 10.1007/s00108-006-1585-z

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  37 in total

1.  Coxibs and cardiovascular disease.

Authors:  Garret A Fitzgerald
Journal:  N Engl J Med       Date:  2004-10-06       Impact factor: 91.245

2.  Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.

Authors:  Julia Hippisley-Cox; Carol Coupland; Richard Logan
Journal:  BMJ       Date:  2005-12-03

3.  Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.

Authors:  Nancy A Nussmeier; Andrew A Whelton; Mark T Brown; Richard M Langford; Andreas Hoeft; Joel L Parlow; Steven W Boyce; Kenneth M Verburg
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

4.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Authors:  Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

5.  Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs.

Authors:  L A García Rodríguez; H Jick
Journal:  Lancet       Date:  1994-03-26       Impact factor: 79.321

Review 6.  Cyclooxygenase in biology and disease.

Authors:  R N Dubois; S B Abramson; L Crofford; R A Gupta; L S Simon; L B Van De Putte; P E Lipsky
Journal:  FASEB J       Date:  1998-09       Impact factor: 5.191

7.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors:  F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

8.  Fatal allergic vasculitis associated with celecoxib.

Authors:  F Schneider; F Meziani; C Chartier; M Alt; A Jaeger
Journal:  Lancet       Date:  2002-03-09       Impact factor: 79.321

9.  Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial.

Authors:  Thomas J Schnitzer; Jannie Beier; Piet Geusens; Paul Hasler; Sanjay K Patel; Ingo Senftleber; Xavier Gitton; Alan Moore; Victor S Sloan; Gyula Poór
Journal:  Arthritis Rheum       Date:  2004-08-15

10.  Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis.

Authors:  S E Gabriel; L Jaakkimainen; C Bombardier
Journal:  Ann Intern Med       Date:  1991-11-15       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.